NEW YORK (GenomeWeb News) – DeCode Genetics and US Preventive Medicine announced today that they have signed a letter of intent to collaborate on offering genetic testing to US Preventive Medicine customers.
Dallas-based US Preventive Medicine offers preventive care, wellness, and disease-management services to employers, consumers, and government agencies. The privately held firm said that it is building a personalized medicine business in the US.
“The signing of the letter of intent with DeCode is significant because we will be the first entity in the US and internationally to offer a full continuum of geographically dispersed, comprehensive solutions for personalized medicine,” Christopher Fey, chairman and CEO of US Preventive Medicine, said in a statement.
Terms of the alliance were not disclosed.